The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,886.00
Bid: 1,858.00
Ask: 1,864.00
Change: 18.00 (0.96%)
Spread: 6.00 (0.323%)
Open: 1,814.00
High: 1,918.00
Low: 1,814.00
Prev. Close: 1,868.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Senior Management Changes

4 Jan 2012 07:00

RNS Number : 9387U
Genus PLC
04 January 2012
 



 

For immediate release 4 January 2012

 

 

 

 

 

 

 

GENUS plc

("Genus" or "the Company")

 

Senior Management Changes

 

Genus, a leading global animal genetics company, announces two senior management changes within the Group.

 

Firstly, Genus is delighted to announce that Catherine Glickman will join the Company as Group Human Resources (HR) Director on January 5th 2012. Catherine will be leading the Group's talent management strategy as well as taking responsibility for engaging, equipping and investing in Genus employees to help the Group deliver its ambitious plans for growth. Catherine will become a member of the Genus Executive Leadership Team and will report directly to Karim Bitar, Chief Executive Officer.

 

Until recently, Catherine was the Head of HR at Tesco, one of the five largest global retailers with over 500,000 employees in 14 countries. During her 20 years at Tesco she was instrumental in developing the HR strategy that helped drive the retailer's strong growth and international expansion in recent years. Overall, she has over 25 years' experience in HR, within Tesco and beyond.

 

Secondly, Denny Funk Ph.D, the Company's Chief Scientific Officer, has also joined the Genus Executive Leadership Team. Dr. Funk will report directly to Karim Bitar, Chief Executive, and will have full responsibility for the Company's research & development (R&D) programme. This will ensure that R&D has a key and highly visible role as Genus pursues its ambitious plans for the future. Dr. Denny Funk was an Associate Professor at the University of Wisconsin-Madison before joining Genus in 1995.

 

Separately, Ian Biggs, formerly Head of Global Product and Business Strategy, has stepped down from his role to pursue other opportunities outside Genus. His primary responsibilities will be assumed by Dr. Denny Funk.

 

Karim Bitar, Chief Executive, commented:

 

 "I am delighted to announce the appointment of such a high calibre and experienced individual as Catherine to the role of Group HR Director. Catherine has been attracted and inspired by the Group's ambitious plans and is as enthusiastic as I am about the opportunities ahead. She will play a major role as she helps shape our talent management strategy."

 

"I would like thank Ian for the contribution he has made to Genus over the years and we wish him all the best for the future. Lastly, I am delighted that Denny has taken overall responsibility for R&D and I look forward to working with him closely as we ensure R&D plays a clear and consistent part in helping Genus meet evolving customer and market needs."

 

 

 

 

 

For further information please contact:

 

Genus plc Tel: 01256 345970

Karim Bitar, Chief Executive

John Worby, Finance Director

 

Buchanan Tel: 0207 466 5000

Charles Ryland, Suzanne Brocks, Catherine Breen

www.buchanan.uk.com 

 

 

This announcement is available on the Genus website, www.genusplc.com

 

 

About Genus

 

Genus creates advances to animal breeding through biotechnology and sells added value products for livestock farming and food producers. Its non-genetically modified organism technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

 

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers' animals produce offspring with greater production efficiency, milk and meat output and quality, and use these to supply the global dairy and meat supply chain.

 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global production and distribution network.

 

With headquarters in Basingstoke, England, Genus companies operate in thirty countries on six continents, with research laboratories located in Madison, Wisconsin, USA

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBJMRTMBJMBLT
Date   Source Headline
1st May 20241:59 pmRNSTotal Voting Rights
22nd Feb 20247:00 amRNSInterim Results
15th Feb 20247:00 amRNSTrading Update
1st Feb 20244:24 pmRNSBlock listing Interim Review
1st Feb 20244:21 pmRNSTotal Voting Rights
12th Dec 20237:00 amRNSNon-Executive Director Appointment
22nd Nov 20231:08 pmRNSResult of AGM
22nd Nov 20237:00 amRNSAGM Trading Update
1st Nov 20234:46 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNSCapital Markets Event
13th Oct 20237:00 amRNSAnnual Report and Annual General Meeting
5th Oct 202310:19 amRNSPos. determination-PRRS resistant pigs-Colombia
2nd Oct 202311:12 amRNSTotal Voting Rights
15th Sep 20231:07 pmRNSDirector/PDMR Shareholding
15th Sep 202310:04 amRNSDirector/PDMR Shareholding
7th Sep 20237:00 amRNSPreliminary Results
25th Aug 20238:35 amRNSNotification of Major Holdings
23rd Aug 20239:25 amRNSDirectorate Change
1st Aug 202311:41 amRNSBlock listing Interim Review
1st Aug 202311:36 amRNSTotal Voting Rights
3rd Jul 202311:02 amRNSTotal Voting Rights
16th Jun 20235:33 pmRNSNational Milk Records plc - Form 8.3
16th Jun 20235:10 pmRNSForm 8.3 (OPD) - National Milk Records plc
8th Jun 20233:51 pmRNSDirector/PDMR Shareholding
7th Jun 20235:11 pmRNSNotification of Major Holdings
7th Jun 20235:08 pmRNSNotification of Major Holdings
5th Jun 20239:12 amRNSAdditional Listing
24th May 20234:54 pmRNSNotification of Major Holdings
18th May 20231:32 pmRNSDirector/PDMR Shareholding
16th May 20236:16 pmRNSDirector/PDMR Shareholding
16th May 20237:00 amRNSTrading Update
9th May 20234:30 pmRNSNotification of Major Holdings
3rd May 20238:44 amRNSTotal Voting Rights
2nd May 20237:00 amRNSShare Award for Incoming CEO
3rd Apr 202311:27 amRNSTotal Voting Rights
3rd Apr 20237:00 amRNSAppointment of Chief Executive Officer Designate
21st Mar 20232:58 pmRNSApplication for Block Listing
6th Mar 202312:53 pmRNSNotification of Major Holdings
2nd Mar 20231:51 pmRNSNotification of Major Holdings
1st Mar 20232:20 pmRNSNotification of Major Holdings
24th Feb 20235:13 pmRNSDirector/PDMR Shareholding
24th Feb 202311:39 amRNSNotification of Major Holdings
23rd Feb 20239:33 amRNSReplacement: Interim Results
23rd Feb 20237:00 amRNSChief Executive Officer Retirement
23rd Feb 20237:00 amRNSInterim Results
21st Feb 20235:03 pmRNSNotification of Major Holdings
10th Feb 20232:08 pmRNSNotification of Major Holdings
1st Feb 202310:00 amRNSBlock listing Interim Review
23rd Nov 20221:02 pmRNSResult of AGM
23rd Nov 20227:00 amRNSAGM Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.